Serotonin and YAP/VGLL4 Balance Correlated with Progression and Poor Prognosis of Hepatocellular Carcinoma

Bo Shu1, Mimi Zhai2, Xiongying Miao3, Chao He4, Chaolin Deng3, Yu Fang4, Ming Luo5, Luyao Liu5 & Sushun Liu1

YAP-TEAD complex plays an important role in tumorigenesis. 5-HT is proved to upregulate YAP expression by our previous study and VGLL4 is found to compete with YAP for binding to TEAD in several of cancers. Here, we investigated whether 5-HT could affect progression and prognosis of hepatocellular carcinoma (HCC) patients and regulate YAP/VGLL4 balance. We found that 5-HT and YAP/VGLL4 ratio were higher in HCC patients and closely related with progression and poor prognosis. Furthermore, 5-HT level, YAP/VGLL4 ratio and tumor size were proved as independent risk factors of HCC patients in our study. Based on the independent risk factors, nomogram was established to exactly predict prognosis of HCC patients. Additionally, the study revealed that a higher total point of the nomogram was closely correlated with poorer prognosis. As a result, 5-HT might contribute to the progression and poor prognosis of hepatocellular carcinoma via regulating YAP/VGLL4 balance. Therefore, the established nomogram based on the independent risk factors may become an important part of HCC prediction system and YAP/VGLL4 balance may be a potential therapeutic target in future.

In China, hepatocellular carcinoma (HCC) reminds the sixth common malignancy and causes the third mortality among different kinds of cancer1. The morbidity of HCC is still increasing every year with poor prognosis. Serotonin (5-HT), a potent mitogen, is proved to be closely associated with liver regeneration as well as hepatocarcinogenesis2,3. Increasing evidence has indicated that serotonin promotes proliferation and invasion of hepatoma cell3,4. Besides, it has been proved to promote proliferation of xenograft in models3,4.

Landmark studies have implicated that YAP plays an essential role in promoting organ size and tumorigenesis5-7. Our previous study also demonstrate that serotonin promotes malignant biological behavior of hepatocellular carcinoma via regulation of YAP. In addition, a 5-HT-5-HT2B receptor-pERK-YAP axis emerged out in this study7. Increasing number of studies indicate that YAP interacts with TEADs to activate target genes though it does not contain any DNA-binding domains. VGLL4, a novel tumor suppressor, is reported to compete with YAP for pairing with TEADs to disrupt the YAP-TEADs complex formation8-11. Further study conducted by Jiao et al. indicated that both YAP and VGLL4 levels should maintain a suitable balance or ratio to control organ development. Disrupting the homeostasis might lead to dysplasia or cancers6. Moreover, Jiao et al. demonstrated that YAP/VGLL4 ratios was sharply upregulated and closely correlated with tumor progress in gastric carcinoma. At present, YAP/VGLL4 balance has been studied in gastric carcinoma, esophageal squamous cell carcinoma, lung cancer and colorectal cancer, but not in HCC so far8,11,12. Based on our previous study, serotonin has the ability to upregulate the expression of YAP9. However, whether YAP/VGLL4 balance is regulated by serotonin remains unknown. Therefore, there is great need to identify the effects of YAP/VGLL4 balance on HCC and the regulation of it induced by serotonin.

In this work, we set out to investigate the whether serotonin is correlated with the prognosis of HCC via regulating YAP/VGLL4 balance, aiming to establish a nomogram prognosis prediction system of HCC as well as developing a potential therapeutic target for HCC patients.
Results

The 5-HT level was higher in HCC patients.

First, we investigated the 5-HT level in serum and plasma, blood platelet count (PLT) in selected patients. Notably, the 5-HT levels in serum were higher in HCC patients as well as the PLT levels (Fig. 1A,C). The 5-HT level in plasma were also higher in HCC patients, but it was not statistically significant (Fig. 1B). In addition, the intraplatelet 5-HT level, platelet extract 5-HT level, intraplatelet 5-HT per platelet and platelet extract 5-HT per platelet were all higher in HCC patients. (H) The platelet extract 5-HT per platelet and intraplatelet 5-HT per platelet were positively correlated. ns: no statistical significance, *P < 0.05, **P < 0.01.

YAP expression upregulated in HCC patients and was positively correlated with 5-HT level.

We assessed the tissular 5-HT level and YAP expression in tissue samples as well. As expected, tissular 5-HT level was higher in HCC which was similar to serum 5-HT level (Fig. 2A). The YAP expression in mRNA and protein level were both upregulated in HCC patients (Fig. 2B,C). Furthermore, correlation analysis was conducted between 5-HT level and YAP expression. As a result, the serum 5-HT level, tissular 5-HT level and intraplatelet 5-HT per platelet were all positively correlated with YAP expression in tissue samples of HCC patients (Fig. 2D–F).

VGLL4 expression downregulated in HCC patients and was negatively correlated with 5-HT level.

To confirm the biological role of VGLL4 in HCC, we measured the VGLL4 expression in tissular samples of HCC patients. Both of the mRNA and protein level of VGLL4 downregulated in HCC patients (Figs 2C and 3A). To examine whether VGLL4 expression was correlated with 5-HT level, we performed several correlation analysis. As shown in Fig. 3B, the serum 5-HT level and VGLL4 mRNA relative expression were negatively correlated. Similar results were obtained in tissular 5-HT and intraplatelet 5-HT per platelet (Fig. 3C,D).

YAP/VGLL4 ratio was correlated with HCC prognosis and 5-HT level.

Because VGLL4 has the competitive inhibition effects on YAP-TEAD complex, we explored the relationship between YAP and VGLL4 expression in tissular samples of HCC patients and found that YAP expression was negatively correlated with VGLL4 expression (Fig. 3E). Next, we calculated the YAP/VGLL4 ratio of each patient and found that the average value of YAP/VGLL4 ratios among all HCC patients were much higher compared with non-tumor patients (Fig. 3F). To further determine the potential effect of YAP/VGLL4 ratio in HCC, correlation analysis was performed. Similar to YAP, YAP/VGLL4 ratio was also positively correlated with serum 5-HT, tissular 5-HT and intraplatelet 5-HT per platelet respectively.
(Fig. 3G–I). Together, these results suggested that YAP/VGLL4 ratio was an important factor correlated with HCC prognosis. Moreover, it might be a potential diagnostic and prognostic marker for HCC patients.

Clinical significance of 5-HT level and YAP/VGLL4 balance in HCC patients. The median of 5-HT level in serum and mean of YAP/VGLL4 ratio in tissue samples were determined as the cutoff value to evaluate the prognosis of HCC patients. Based on the analysis of clinical database, we found that high 5-HT level was prominently related to higher PLT ($P < 0.001$), larger tumor size ($P < 0.001$), more death ($P = 0.002$) and higher YAP/VGLL4 ratio ($P = 0.016$) and high YAP/VGLL4 ratio was related to higher ALP ($P = 0.010$), higher GGT ($P < 0.001$) and larger tumor size ($P < 0.001$), easier vascular invasion ($P = 0.001$), more death ($P < 0.001$) and a higher 5-HT level ($P = 0.016$) (Table 1). Additionally, ALP, GGT, tumor size, 5-HT level and YAP/VGLL4 ratio were all associated with overall survival and recurrence-free survival via univariate analysis (Table 2). Multivariate analysis demonstrated that only tumor size, 5-HT level and YAP/VGLL4 ratio were associated with overall survival and recurrence-free survival synchronously (Table 3). Survival analysis further revealed that higher level of 5-HT and YAP/VGLL4 ratio were both associated with a lower overall survival, shorter recurrence-free survival and poorer prognosis of HCC patients (Fig. 4A–D).

Predictive nomogram for survival. To predict the survival of HCC patients, prognostic nomogram was established via R software using independent risk factor consisting of tumor size, 5-HT level, YAP/VGLL4 ratio. Based on the nomogram, we can predict the one-year and three-year survival rate for HCC patients (Fig. 4E). In addition, calibration plots of the established nomogram were conducted and performed well with the ideal model (Fig. 4F,G). On the basis of these results, it indicated that higher total point of the nomogram mean poorer prognosis of HCC patients.

Discussion
Nowadays, serotonin in the central nervous system is well studied. Besides, peripheral serotonin also plays an essential role in regulating organ system, especially in promoting tumor process and cell proliferation. Our previous study have demonstrated that serotonin promotes malignant biological behavior of hepatocellular carcinoma...
via regulating YAP expression. However, how the HCC process affected by YAP expression is still confusing. In this study, we demonstrated that 5-HT level affected the HCC prognosis via regulating YAP/VGLL4 balance. 5-HT and YAP/VGLL4 balance were closely related with prognosis of HCC patients. Moreover, established nomogram has the ability to accurately predict the survival of HCC patients.

Accumulated studies indicated that 5-HT acted as a mitogen in different kinds of cancer. Starlinger et al. study demonstrated that 5-HT was a relevant inducer in liver regeneration. Additionally, studies conducted by Soll et al. and Liang et al. also revealed that 5-HT promoted hepatoma cell proliferation. Similarly, our previous study demonstrated that serum 5-HT level, platelets, intraplatelet 5-HT and platelet extract 5-HT in HCC patients were all higher. On the contrary, there was no statistical significance in plasma 5-HT between the two groups. Because decoagulant was used during the plasma preparation process, platelets were inactivated and 5-HT were still retained in platelets. Oppositely, the platelets were activated during the process of serum preparation, and 5-HT were released from the activated platelets. As a result, 5-HT level was higher only in serum between the two groups.
Accumulating studies have reported that YAP and VGLL4 function as regulators of the Vestigial-like proteins, has emerged as a new TEAD-interacting factor. An increasing number of studies indicated that VGLL4 inhibited proliferation by disrupting YAP-TEAD interaction and targeting TEAD for degradation. VGLL4 ratio were sharply skewed and well correlated with tumor progression in gastric cancer. Similar results were obtained by Zhang et al. YAP/VGLL4 balance might play an important role in tumorigenesis and prognosis. A study conducted by Jiao et al. demonstrated that YAP expression was down-regulated by YAP-siRNA, the VGLL4 expression was not affected by it (supplementary materials). Taken together, 5-HT level might affect prognosis of hepatocellular carcinoma via regulating the YAP/VGLL4 balance.

Table 1. Basic characteristics of HCC patients stratified according to the 5-HT level and YAP/VGLL4 balance.

| Variable                      | Overall | 5-HT (n = 62) | Higher (n = 62) | P     | YAP/VGLL4 ratio | Lower (n = 47) | Higher (n = 77) | P     |
|-------------------------------|---------|---------------|----------------|-------|-----------------|---------------|----------------|-------|
| Sex, male/female              | 98/26   | 51/11         | 47/15          | 0.379 | 36/11           | 62/15         | 0.604          |
| Age (ys)                      | 51.1 ± 9.8 | 51.4 ± 9.5    | 50.8 ± 10.0    | 0.742 | 51.2 ± 11.3     | 51.1 ± 8.8    | 0.948          |
| ALT (U/L)                     | 47.5 (11–492) | 44 (11–359)    | 52 (13–492)    | 0.615 | 41 (11–492)     | 53 (13–433)   | 0.460          |
| AST (U/L)                     | 46 (13–561) | 41 (13–356)    | 53 (17–561)    | 0.119 | 40 (13–561)     | 48 (17–330)   | 0.070          |
| ALP (U/L)                     | 97 (26–388) | 92 (26–241)    | 105 (56–388)   | 0.178 | 88 (36–173)     | 110 (26–388)  | 0.010          |
| GGT (U/L)                     | 69.5 (13–803) | 59 (13–381)    | 83 (14–803)    | 0.235 | 44 (15–274)     | 90 (13–803)   | <0.001         |
| PLT (10^9/L)                  | 124 (25–417) | 100 (25–227)   | 145 (32–417)   | <0.001 | 112 (51–417)   | 132 (25–351)  | 0.476          |
| INR (U/L)                     | 1.1 (0.8–1.6) | 1.1 (0.8–1.6)  | 1.1 (0.8–1.6)  | 0.161 | 1.1 (0.8–1.4)   | 1.1 (0.8–1.6) | 0.327          |
| ALB                           | 39 (19–52) | 38 (19–52)     | 39 (28–51)     | 0.503 | 39 (19–52)      | 39 (24–51)    | 0.013          |
| AFP: ≥200/<200                | 62/55   | 36/23          | 36/23          | 0.079 | 19/25           | 43/30         | 0.099          |
| Aschtes: yes/no               | 14/110  | 5/57           | 9/53           | 0.256 | 3/44            | 11/66         | 0.177          |
| Cirrhosis: yes/no             | 51/73   | 29/33          | 22/40          | 0.201 | 20/27           | 31/46         | 0.801          |
| Tumor size: ≥5/≤5 cm          | 56/68   | 16/46          | 40/22          | <0.001 | 6/41           | 50/27         | <0.001         |
| Tumor number: multiple/single  | 30/94   | 14/48          | 16/46          | 0.675 | 7/40            | 23/54         | 0.059          |
| Child-Pugh: A/B + C           | 111/13  | 57/5           | 54/8           | 0.379 | 44/3            | 67/10         | 0.244          |
| Vascular invasion: yes/no     | 16/108  | 4/58           | 12/50          | 0.032 | 0/47            | 16/61         | 0.001          |
| Death: yes/no                 | 40/84   | 12/52          | 28/34          | 0.002 | 6/41            | 34/43         | <0.001         |
| YAP/VGLL4 ratio: high/low     | 77/47   | 32/30          | 45/17          | 0.016 | 17/30           | 45/32         | 0.016          |
| 5-HT: high/low                | 62/62   |                |               |       |                 |               |               |

As an oncogene, YAP can promote proliferation and migration of diverse cancer cells via activating target genes, such as CTGF, AREG and et al. Tho...
Our study firstly explored regulating effect of 5-HT on YAP/VGLL4 balance. We further explored the relationship of 5-HT, YAP/VGLL4 balance and prognosis. Additionally, the nomogram based on tumor size, 5-HT and YAP/VGLL4 balance were established in our study. Using the nomogram, we could accurately predict prognosis of HCC patients. Moreover, regulating YAP/VGLL4 balance might be a potential therapeutic method for HCC patients in the further.

**Materials and Methods**

**Patients.** From January 2014 to June 2015, a total of 124 HCC patients and 21 hepatic hemangioma patients undergoing partial hepatectomy at the The Second Xiangya Hospital of Central South University were selected in our study. The inclusion criteria of tumor group were as follows: (1) First diagnosed and meet the National Comprehensive Cancer Network (NCCN) criteria of hepatocellular carcinoma, (2) Not received radiotherapy, chemotherapy before hepatectomy, (3) there were no co-occurrences of other cancers, (4) not received splenectomy, (5) not use medication and not suffered from diseases that affected the function and count of platelet. The inclusion criteria for non-tumor group was same with tumor group expected for the first criteria.

| Sex, male vs. female | uHR (0.345–1.337) | 0.264 |
|----------------------|-------------------|-------|
| Age (ys)             | 1.006 (0.973–1.039) | 0.735 |
| ALT (U/L)            | 1.000 (0.996–1.003) | 0.800 |
| AST (U/L)            | 1.001 (0.997–1.004) | 0.654 |
| ALP (U/L)            | 1.007 (1.003–1.012) | 0.002 |
| GGT (U/L)            | 1.003 (1.001–1.005) | 0.015 |
| PLT (10^9/L)         | 1.001 (0.997–1.005) | 0.714 |
| INR                  | 1.490 (0.178–12.50) | 0.713 |
| ALB                  | 0.899 (0.939–1.046) | 0.748 |
| AFP ≥ 200 vs. < 200 (ng/ml) | 1.110 (0.589–2.092) | 0.746 |
| Ascites, yes vs. no  | 1.423 (0.557–3.638) | 0.461 |
| Cirrhosis, yes vs. no | 1.192 (0.631–2.252) | 0.588 |
| Tumor size, ≥5 vs. < 5 cm | 3.784 (1.933–7.333) | <0.001 |
| Tumor number, multiple vs. single | 1.521 (0.770–3.006) | 0.227 |
| Child-pugh, B+C vs. A | 1.015 (0.361–2.850) | 0.978 |
| Vascular invasion: yes vs. no | 1.634 (0.682–3.910) | 0.270 |
| 5-HT, high vs. low   | 3.320 (1.651–6.674) | 0.001 |
| YAP/VGLL4 ratio, high vs. low | 5.529 (2.269–13.473) | <0.001 |

**Table 2.** Univariate and multivariate analysis of factors associated with overall survival of HCC patients.

| Sex, male vs. female | uHR (0.345–1.337) | 0.264 |
|----------------------|-------------------|-------|
| Age (ys)             | 1.006 (0.973–1.039) | 0.735 |
| ALT (U/L)            | 1.000 (0.996–1.003) | 0.800 |
| AST (U/L)            | 1.001 (0.997–1.004) | 0.654 |
| ALP (U/L)            | 1.007 (1.003–1.012) | 0.002 |
| GGT (U/L)            | 1.003 (1.001–1.005) | 0.015 |
| PLT (10^9/L)         | 1.001 (0.997–1.005) | 0.714 |
| INR                  | 1.490 (0.178–12.50) | 0.713 |
| ALB                  | 0.991 (0.939–1.046) | 0.748 |
| AFP ≥ 200 vs. < 200 (ng/ml) | 1.110 (0.589–2.092) | 0.746 |
| Ascites, yes vs. no  | 1.423 (0.557–3.638) | 0.461 |
| Cirrhosis, yes vs. no | 1.192 (0.631–2.252) | 0.588 |
| Tumor size, ≥5 vs. < 5 cm | 3.784 (1.933–7.333) | <0.001 |
| Tumor number, multiple vs. single | 1.521 (0.770–3.006) | 0.227 |
| Child-pugh, B+C vs. A | 1.015 (0.361–2.850) | 0.978 |
| Vascular invasion: yes vs. no | 1.634 (0.682–3.910) | 0.270 |
| 5-HT, high vs. low   | 3.320 (1.651–6.674) | 0.001 |
| YAP/VGLL4 ratio, high vs. low | 5.529 (2.269–13.473) | <0.001 |

**Table 3.** Univariate and multivariate analysis of factors associated with recurrence-free survival of HCC patients.
For each patient, the clinical and pathologic data was gathered via electronic medical records as follow: age, gender, aspartate transaminase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), γ-glutamyl transpeptidase (γ-GGT), albumin (ALB), international normalized ratio (INR), platelet count (PLT), alpha-fetoprotein (AFP), ascites, cirrhosis, tumor sizes, tumor number, Child-Push, vascular invasion, pathologic reports and death.

Follow-up survey was conducted by two independent investigators, who had no knowledge of the study. All of the patients were follow up every 3 months until April 2017. Patient who lost touch with us for four times

Figure 4. High 5-HT level and YAP/VGLL4 ratio were correlated with poor prognosis and indicated a low overall survival and short recurrence-free survival. (A, B) HCC patients with a higher level of 5-HT had poorer overall survival (A) and recurrence-free survival (B). (C, D) HCC patients with a higher YAP/VGLL4 ratio had poorer overall survival (C) and recurrence-free survival (D). (E–G) Nomogram for predicting the 1- and 3-year survival of HCC patients (E) and the calibration plot of the nomogram for 1 year (F) and 3 years (G). ns: no statistical significance, *P < 0.05, **P < 0.01.
in succession would be excluded in our study. All selected patients were treated based on the Clinical Practice Guidelines for Hepatocellular Carcinoma established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. Before analysis of blood samples and patient data in our study, the informed consent from the patients and the approval from the Central South University Ethics Committee were both obtained. Study was performed in accordance with the ethical standards of the Committee on Human Experimentation and the Helsinki Declaration.

Sample preparation. Routine blood samples as well as serum and plasma preparation were conducted before the surgery. Additionally, tissue samples of all patients were collected during the operation. Notably, 5-HT is stored in alpha granules of platelet. During the preparation of blood samples, the 5-HT might be released by artificial activation of platelets in vitro. Thus, an optimized technique was applied base on Starlinger's study. Briefly, blood sample was drawn into CTAD tube and placed on ice immediately. Then the sample was subject to an initial centrifugation at 1000 g in 4 °C for 10 minutes and following centrifugation was conducted at 10000 g in 4 °C for 10 minutes to remove remaining platelets. Finally, the supernatant was stored at −80 °C.

Serum sample of selected patients was collected without addition of anti-coagulants and centrifuged at 1000 g in room temperature for 30 minutes. The supernatant was collected and also stored at −80 °C.

In order to obtain the platelet extract, the blood sample was drawn into tube with trisodium citrate and centrifuged at 125 * g for 20 minutes. Then the supernatant was wash by HEPES-tyrode buffer for three times. Finally, the washed platelets were resuspended in lysis buffer to generate platelet extract.

Quantification of 5-HT. The level of 5-HT in serum, plasma and platelet extracts were measured via human 5-HT ELISA Kit according to the manufacturer's instruction. Because the serum 5-HT level was the whole 5-HT which was released after platelet activation, and the plasma 5-HT level was the circulating amount of 5-HT. The actual level of intraplatelet 5-HT level was calculated as dividing the plasma 5-HT level from the serum 5-HT level. The intraplatelet 5-HT per platelet was calculated as dividing intraplatelet 5-HT level by platelet counts. Similarly, the platelet extract 5-HT per platelet was calculated as dividing the platelet extract 5-HT level by platelet counts.

RNA isolation and quantitative real-time PCR (qRT-PCR). TRIZol reagent (Invitrogen, Carlsbad, CA, USA) was to extract the total RNA from tissue samples. The SYBR Premix Ex Taq Kit (Takara, Tokyo, Japan) and TaqMan microRNA assays (Applied Biosystems, Foster City, CA, USA) were used to conduct qRT-PCR. The RNA expression was calculated via the relative quantification method. The primers were shown as follow.

Western blot analysis. Proteins were extracted from the tissue samples according to the manufacturer's instruction. Western blot analysis were conducted as previously described. The antibodies used in the study were shown as follow: anti-YAP (ab205270, Abcam, Cambridge, MA, USA), VGLL4 (ab140290, Abcam, Cambridge, MA, USA).

Statistical analysis. The data were expressed as mean ± standard deviation (SD). The correlation differences between the respective groups were evaluated by either analysis of variance (ANOVA) or nonparametric test, as applicable, using SPSS v20 (SPSS, IBM Inc.). The correlation between 5-HT level and YAP expression, 5-HT level and VGLL4 expression, YAP expression and VGLL4 expression, 5-HT level and YAP/VGLL4 ratio were evaluated by Pearson's correlation analysis. Because the amount of selected patient was 124, the optimal cut-off level of 5-HT was determined as median rather than receiver operating curve (ROC) analysis. The cut-off of YAP/VGLL4 ratio was determined as mean, because the value of YAP/VGLL4 ratio could be considered to obey normal distribution. Overall survival was calculated as the time from the date of hepatectomy until death or the last follow-up survey. Recurrence-free survival was calculated as the time from the date of hepatectomy until death, tumor recurrence or end of the follow-up. In addition, the survival curves were plotted by K-M method. A nomogram for the 5-HT level and YAP/VGLL4 ratio, which were associated with survival, was established using rms package of R software (R 3.2.1 software, Institute for Statistics and Mathematics). The selected factors in nomogram were based on multivariate analysis of factors which was associated with overall survival and recurrence-free survival of HCC patients. Calibration plots were conducted to evaluate the performance characteristics of the predictive nomogram. P-value less than 0.05 was considered statistically significant.

References
1. Ferenci, P. et al. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 44, 239–245, https://doi.org/10.1097/MCG.0b013e3181d46ef2 (2010).
2. Leurtel, M. & Clavien, P. A. Platelet-derived serotonin: translational implications for liver regeneration. Hepatology 60, 30–33, https://doi.org/10.1002/hep.27067 (2014).
3. Soll, C. et al. Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology 51, 1244–1254, https://doi.org/10.1002/hep.23441 (2010).
4. Liang, C. et al. Serotonin promotes the proliferation of serum-deprived hepatocellular carcinoma cells via upregulation of FOXO3a. Molecular cancer 12, 14, https://doi.org/10.1186/1476-4598-12-14 (2013).
5. Zhang, L. et al. The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells. *Molecular and cellular biology* **35**, 1350–1362, doi:10.1128/MCB.00102-15 (2015).

6. Kowalk, M. A. et al. Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice. *Hepatology* **53**, 2086–2096, doi:10.1002/hep.24289 (2011).

7. Liu, S. et al. Effects and related mechanisms of serotonin on malignant biological behavior of hepatocellular carcinoma via regulation of YAP: Oncotarget, doi:10.18632/oncotarget.1768 (2017).

8. Jiao, S. et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. *Cancer cell* **25**, 166–180, doi:10.1016/j.ccr.2014.01.010 (2014).

9. Zhang, W. et al. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. *Cell Res* **24**, 331–343, doi:10.1038/cr.2014.10 (2014).

10. Li, H. et al. VGLL4 inhibits EMT in part through suppressing Wnt/beta-catenin signaling pathway in gastric cancer. *Medical oncology* **32**, 83, doi:10.1007/s12032-015-0539-5 (2015).

11. Jiao, S. et al. VGLL4 targets a TCF4-TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer. *Nature communications* **8**, 14058, doi:10.1038/ncomms14058 (2017).

12. Jiang, W. et al. Downregulation of VGLL4 in the progression of esophageal squamous cell carcinoma. *Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine* **36**, 1289–1297, doi:10.1007/s12054-012-1701-7 (2015).

13. Starlinger, P. et al. Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans. *Hepatology* **60**, 257–266, doi:10.1002/hep.26950 (2014).

14. Zhao, B. et al. TEAD mediates YAP-dependent gene induction and growth control. *Genes & development* **22**, 1962–1971, doi:10.1101/gad.1866448 (2008).

15. Hao, Y., Chen, A., Cheung, K., Rashidi, B. & Yang, X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. *The Journal of biological chemistry* **283**, 5496–5509, doi:10.1074/jbc.M709037200 (2008).

16. Perra, A. et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. *J Hepatology* **61**, 1088–1096, doi:10.1016/j.jhep.2014.06.033 (2014).

17. Wang, J. et al. Mutual interaction between YAP and CREB promotes tumorigenesis in liver cancer. *Hepatology* **58**, 1011–1020, doi:10.1002/hep.26420 (2013).

18. Lin, Z. et al. Acetylation of VGLL4 Regulates Hippo–YAP Signaling and Postnatal Cardiac Growth. *Developmental cell*, doi:10.1016/j.devcel.2016.09.005 (2016).

19. Tajonar, A. et al. Brief report: VGLL4 is a novel regulator of survival in human embryonic stem cells. *Stem Cells* **31**, 2833–2841, doi:10.1002/stem.1445 (2013).

20. Zhang, Y. et al. VGLL4 Selectively Represses YAP-Dependent Gene Induction and Tumorigenic Phenotypes in Breast Cancer. *Sci Rep* **7**, 6190, doi:10.1038/s41598-017-06227-7 (2017).

21. Janyong, L., Zhihui, L., Rixiang, G. & Jingqiang, Z. Using a nomogram based on preoperative serum fibrinogen levels to predict recurrence of papillary thyroid carcinoma. *BMC cancer* **18**, 390, doi:10.1186/s12885-018-4296-7 (2018).

22. He, C. et al. Nomograms predict long-term survival for patients with periampullary adenocarcinoma after pancreatoduodenectomy. *BMC cancer* **18**, 327, doi:10.1186/s12885-018-4240-x (2018).

23. Goense, L. et al. Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma. *Annals of surgical oncology*, doi:10.1245/s10434-018-6435-4 (2018).

24. Narita, Y. et al. Establishment and validation of prognostic nomograms in first-line metastatic gastric cancer patients. *J Gastrointest Oncol* **9**, 52–63, doi:10.21037/jgo.2017.11.08 (2018).

25. Mao, Q. et al. A nomogram to predict the survival of stage IIIA-N2 non-small cell lung cancer after surgery. *J Thorac Cardiovasc Surg* **155**, 1784–1792 e1783, doi:10.1016/j.jtcvs.2017.11.098 (2018).

26. Hsu, C. Y. et al. Using nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage C hepatocellular carcinoma. *BMC cancer* **18**, 289, doi:10.1186/s12885-018-4202-3 (2018).

27. Liu, S. et al. The Protective Role of Curcumin in Zymosan-Induced Multiple Organ Dysfunction Syndrome in Mice. *Shock* **45**, 209–219, doi:10.1097/ZSH.0000000000000502 (2016).

**Acknowledgements**

We are indebted to individuals who have participated in or have helped with this article.

**Author Contributions**

Shu B. and Zhai M.M. analyzed the data and wrote the manuscript; Miao X.Y. and Fang Y. analyzed the data; He C., Deng C.L. and Liu L.Y. created the figures; Luo M. revised the manuscript; Liu S.S. designed study, contributed discussion and edited the manuscript as corresponding author.

**Additional Information**

**Supplementary information** accompanies this paper at https://doi.org/10.1038/s41598-018-28075-9.

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018